Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Jmk2454on Dec 24, 2019 7:48am

61 Views

Post# 30486887

RE:TROLL FREE DISCUSSION

Jack4000 wrote:
Tired of these same well refuted arguments popping up again and again by trolls? Here’s a place with no repetitious bashing and lying - a place where even the trolls behave - and yes, so popular even our Stockhouse troll is an interested member who posts regularly - and civilly rather than the gibberish he’s so well known for here.

https://join.slack.com/t/kalytera/shared_invite/enQtODY2NTUwOTk0MTY3LWU2YTMzYTMyM2I5MzlhZWNiODJlNjViYWIxZDBmZTBmZDQ1MjU5MTRjMGI0ZmI3ZjM0ZWYyNGRjMmRhN2EyOWU

now moving it up past troll posts.

Bullboard Posts

BlackBerry: 600,000 cyberattacks on critical infrastructure in Q3 2024